Protect\_Child\_101 is an observational study to be performed in children that have undergone a liver or renal transplant. The aim of this study is to analyse small variations in the genetic material (DNA) of transplanted children. The investigators will also study a type of chemical 'marks' called methylations, which do not change the DNA itself, but can affect how it functions. These marks can influence how certain diseases develop or how the body responds to transplantation. Specifically, investigators seek to discover: * Whether there are genetic or epigenetic (methylation) alterations that may explain why some children develop serious diseases that require transplantation. * If these alterations can help us predict possible complications after transplantation, such as organ rejection, infections, organ failure, cancer development. Within this study, data from the child's medical history will be collected. The data to be collected are demographic data (gender, age, ethnicity), clinical data, personal and family history possibly related to his/her disease, course and evolution of the disease, and complementary and laboratory examinations collected from his/her clinical history. The only non-routine tests to be performed will be the genomic and methylomic tests. Nevertheless, these determinations will be performed on samples obtained during the child's routine care. No extra intervention is planned as part of this study. Samples and clinical data will be collected at different time points after transplantation. Schematically, collection is planned for months 0, 1, 3, 6, 12 and 24 post-transplant. In addition to these pre-established points, comprehensive data collection will be attempted when the child suffers a relevant clinical event, e.g. infection, treatment toxicity, organ rejection (post-transplant complication).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Epstein Barr Infection
Timeframe: From transplant until end of post-transplant follow-up period (up to 7years)
Cytomegalovirus infection
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
BK virus infection
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
Cholangitis
Timeframe: From transplant until end of post-transplant follow-up period
Urinary Tract Infection
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
Sepsis
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
Renal Calcineurin Inhibitors toxicity
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
Mycophenolate mofetil toxicity
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
mTOR inhibitor toxicity
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
Thrombotic microangiopathy
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
Kidney rejection episode
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
Liver rejection episode
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
Chronic liver rejection
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
Chronic kidney rejection
Timeframe: From transplant until end of post-transplant follow-up period (up to 7 years)
Chronic renal failure after pLTx
Timeframe: From transplant until end of post-transplant follow up period (up to 7 years)
Chronic liver failure (graft chirrosis and fibrosis)
Timeframe: From transplant until end of post-transplant follow up period (up to 7 years)